Earnings per share for the last twelve months: Y-mAbs Therapeutics Inc (YMAB)
Y-mAbs Therapeutics (YMAB) combines powerful scientific and technical potential in pediatric oncology radioimmunotherapy with the commercialization of precision antibodies to combat metastases. The current level of rolling earnings per share visualizes this balance, where -0.49 expresses the metric's value today. The biotech's financial stability is supported by steady revenue from the sale of Danyelza, which creates a reliable cash flow driven by niche demand.
Analytical breakdowns for Y-mAbs Therapeutics
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Y-mAbs Therapeutics|YMAB - Long-Term Indebtedness to Equity|Short-Term Debt to Equity ymabs.com|YMAB - Company Total Debt|Debts to Book Capitalization Y-mAbs Therapeutics Inc|YMAB - Company Long-Term Debts|Company Short-Term Debts Y-mAbs Therapeutics|Quick Liquidity ymabs.com
- net income and valuation multiples indicators:
YMAB - Net Financial Result|Future Profit Y-mAbs Therapeutics|YMAB - Company Value to Net Income|Projected Price to Earnings Y-mAbs Therapeutics, Inc.|YMAB - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Y-mAbs Corp|YMAB - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Y-mAbs Therapeutics|YMAB - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months ymabs.com|YMAB - Earnings per share increase in current year|Earnings growth forecast for next year Y-mAbs Therapeutics
- revenue and sales proceeds data:
Initial company analysis:ymabs.com (YMAB)
Trailing twelve-month earnings per share (EPS TTM) reflects the portion of total income attributable to a single security, allowing investors to assess the actual return on equity without accounting for dilution. By analyzing the earnings per share over the last 12 months, one can determine how effectively Y-mAbs Therapeutics (YMAB) monetizes its orphan drug patents, despite high production costs and the logistical complexities associated with pediatric oncology.
Competitors of Y-mAbs Therapeutics (YMAB)
ONC - Earnings per share for the last twelve months|HALO - Net earnings per share (EPS TTM)|RevMed (RVMD) - Earnings per share for the last twelve months|Ascentage - Earnings per share for the trailing year|CGON (CG Oncology Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma URGN|Net earnings per share (EPS TTM) BCAX|PSNL: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Erasca Corp ERAS|Delcath Corp (DCTH) - Net earnings per one share for the last twelve months|AURA - Earnings per share for the last twelve months|CADL (candeltx.com) - Earnings per share for the last 12 months|ARAY (accuray.com) - Net earnings per share for the last 12 months|SELLAS Life Sciences Group Inc. (SLS) - Net earnings per share (EPS TTM)|ACTU (Actuate Therapeutics Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Citius Oncology Inc|Net earnings per share (EPS TTM) HURA|TARA (Protara Therapeutics) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) FATE (Fate Therapeutics)|Net earnings per share for the last four quarters Aadi Bioscience Inc (WHWK)|TScan Therapeutics, Inc. - Net earnings per share (EPS TTM)|CSBR (Champions Oncology, Inc.) - Earnings per share for the last 12 months|XBIT (XBiotech USA) - Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months CEL-SCI Corp (CVM)|OSTX (OS Therapies Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Radiopharm Theranostics (RADX)|Net earnings per share for the last 12 months ARTV (Artiva Biotherapeutics, Inc.)|ANL - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Veru Inc. VERU|Earnings per share for the trailing year TPST|XLO: Net earnings per share for the last 12 months|Net earnings per share for the last four quarters Renovaro RENB|MURA (muraloncology.com) - Net earnings per share for the last 12 months|Kairos Pharma Inc - Earnings per share for the trailing year|Net earnings per share for the last 12 months OKUR|Net earnings per one share for the last twelve months CytoMed Therapeutics Limited GDTC|Net earnings per share (EPS TTM) CRIS|Net earnings per share (EPS TTM) Apollomics Inc. (APLM)|Net earnings per share (EPS TTM) THAR (Tharimmune Corp)|Net earnings per share for the last four quarters Advanced Biomed Inc (ADVB)|Genprex Inc - Net earnings per share (EPS TTM)|CLDI - Net earnings per share (EPS TTM)|Sunshine Biopharma Inc. (SBFM) - Earnings per share for the last twelve months|XBIO - Net earnings per share for the last four quarters|SLRX (Salarius Pharma) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Kitov Pharma|Net earnings per share for the last 12 months AONC (American Oncology Network)|BGNE - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CKPT (Checkpoint Therapeutics Inc.)|Elevation Oncology, Inc. - Earnings per share for the last twelve months|ICAD - Earnings per share for the last twelve months|IKNA - Net earnings per share (EPS TTM)|Notable Labs (NTBL) - Earnings per share for the last twelve months|Earnings per share for the last 12 months VIRX|MOR (MorphoSys Corporation) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NAYA Biosciences Inc NAYA|Earnings per share for the last twelve months Ascentage Pharma (AAPGV)
